Skip to content

APrevent Vocal Implant System (VOIS) for Adjustable Treatment of Unilateral Vocal Fold Paralysis (UVFP)

APrevent Vocal Implant System (VOIS) for Adjustable Treatment of Unilateral Vocal Fold Paralysis (UVFP) - an Open-label, Non-randomized Pilot Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03864757
Enrollment
8
Registered
2019-03-06
Start date
2018-07-05
Completion date
2019-02-21
Last updated
2019-03-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Paralysis, Unilateral, Vocal Cord

Keywords

unilateral vocal fold paralysis, type I thyroplasty

Brief summary

The objective of this study is to evaluate pre- and intraoperative voice quality, the degree of vocal fold closure and the Maximum Phonation Time (MPT), first determined after temporary APrevent® VOIS implantation and then after permanent existing product implantation.

Interventions

DEVICEthyroplasty implant

Short-term implantation of thyroplasty implant, VOIS, and evaluation of voice quality and glottal closure. After evaluation, remove VOIS and perform medialization of vocal folds using conventional thyroplasty.

Sponsors

APrevent Biotech GmbH
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DEVICE_FEASIBILITY
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Male and female patients between 18 and 80 years * Diagnosed with permanent UVFP and insufficient glottal closure and planned type I thyroplasty with conventional implant * Ability to co-operate with the investigator and to comply with the requirements of the entire study

Exclusion criteria

* Any other significant disease or disorder which, in the opinion of the investigator, may either put the participant at risk because of participation in the clinical investigation may influence the result of the clinical investigation, or the participant's ability to participate in the clinical investigation * Scheduled elective surgery or other procedures requiring general anaesthesia during clinical investigation * Had medialization thyroplasty before * Had injection medialization laryngoplasty in the past two years. * Presence of structural vocal fold lesions such as polyp or nodules * Status post total cordectomy * Previous laryngeal framework surgery (any type of thyroplasty, arytenoid adduction) * Significant non-laryngeal speech abnormality (severe dysarthria determined by a panel of trained speech therapists) * Severe coagulopathy

Design outcomes

Primary

MeasureTime frameDescription
Change in voice quality by RBH-Scalepre-surgery, right after temporarily implantationRoughness(R), Breathiness(B), Hoarseness(H) Scale will be rated on a 4-point severity scale (0, normal; 1, mild deviance; 2, moderate deviance; and 3, severe deviance).
Change in Glottal closure by Södersten and Lindestad classificationpre-surgery, right after temporarily implantation
Change in maximum phonation time in secondspre-surgery, right after temporarily implantationThe prolongation of a/a:/, for as long as possible after maximal inspiration, and at a spontaneous, comfortable pitch and loudness.

Secondary

MeasureTime frameDescription
Evaluation of surgical handling and device fitting using a VAS scaleright after temporarily implantationVisual analogue scale(VAS) of Subjective Surgeon Satisfaction will be rated from 0 to 10. (0= not satisfied, 10= very satisfied)

Countries

Austria

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026